Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (51-60 of 175) with videos related to

Pageof 18
Sort By:
JTO Clinical and Research Reports|September 30, 2021
Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for <i>MET</i>-Amplified Tumors With <i>MET</i>-D1228X or <i>MET</i>-Y1230X MutationsAndrew J Piper-Vallillo, Susumu S Kobayashi, Daniel B Costa
Lung Cancer (Amsterdam, Netherlands)|July 6, 2007
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersDaniel B Costa, Susumu Kobayashi, Daniel G Tenen, et al.
Clinical Lung Cancer|April 23, 2016
Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late RecurrenceXin Gao, Paul A VanderLaan, Alexandra S Bailey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutationsDaniel B Costa, Susan T Schumer, Daniel G Tenen, et al.
Blood|September 10, 2005
A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindredDaniel B Costa, Larisa Lozovatsky, Patrick G Gallagher, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2013
Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancerNeeharika Srivastava, Paul A VanderLaan, Ciaran P Kelly, et al.
Cancer Cytopathology|August 29, 2024
Comparative genomic and immunopathologic analysis of lung adenocarcinomas with and without cytology-proven malignant pleural effusionsCristiana M Pineda, Adnan Majid, Daniel B Costa, et al.
JACC. Cardiooncology|August 16, 2021
Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor OsimertinibAndrew J Piper-Vallillo, Daniel B Costa, Marwa A Sabe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 24, 2012
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancerHiroyuki Yasuda, Lorena L de Figueiredo-Pontes, Susumu Kobayashi, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 12, 2005
Diabetes mellitus as the presenting feature of extrahepatic cholangiocarcinoma in situ: case report and review of literatureDaniel B Costa, Andrew A Chen, Esmeralda C Marginean, et al.
Pageof 18

Showing results (51-60 of 175) with videos related to

Sort By:
Pageof 18
JTO Clinical and Research Reports|September 30, 2021
Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for <i>MET</i>-Amplified Tumors With <i>MET</i>-D1228X or <i>MET</i>-Y1230X MutationsAndrew J Piper-Vallillo, Susumu S Kobayashi, Daniel B Costa
Lung Cancer (Amsterdam, Netherlands)|July 6, 2007
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersDaniel B Costa, Susumu Kobayashi, Daniel G Tenen, et al.
Clinical Lung Cancer|April 23, 2016
Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late RecurrenceXin Gao, Paul A VanderLaan, Alexandra S Bailey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutationsDaniel B Costa, Susan T Schumer, Daniel G Tenen, et al.
Blood|September 10, 2005
A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindredDaniel B Costa, Larisa Lozovatsky, Patrick G Gallagher, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2013
Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancerNeeharika Srivastava, Paul A VanderLaan, Ciaran P Kelly, et al.
Cancer Cytopathology|August 29, 2024
Comparative genomic and immunopathologic analysis of lung adenocarcinomas with and without cytology-proven malignant pleural effusionsCristiana M Pineda, Adnan Majid, Daniel B Costa, et al.
JACC. Cardiooncology|August 16, 2021
Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor OsimertinibAndrew J Piper-Vallillo, Daniel B Costa, Marwa A Sabe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 24, 2012
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancerHiroyuki Yasuda, Lorena L de Figueiredo-Pontes, Susumu Kobayashi, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 12, 2005
Diabetes mellitus as the presenting feature of extrahepatic cholangiocarcinoma in situ: case report and review of literatureDaniel B Costa, Andrew A Chen, Esmeralda C Marginean, et al.
Pageof 18